XTalks

FEBRUARY 8, 2024

The top 15 diabetes drugs in 2023, according to 2022 sales data, reflect the current state of diabetes management and hint at the evolving needs and trends within this critical area of healthcare. Read on to learn more about the top 15 diabetes drugs in 2023, based on 2022 sales statistics. mL subcutaneous solution (2 mg/1.5

Sales 52

Sales Insulin FDA Approval Drugs 52

XTalks

NOVEMBER 9, 2022

Since Mounjaro’s May US Food and Drug Administration (FDA) approval, sales of the drug have skyrocketed beyond initial expectations owing to patient demand and a temporary shortage of Novo’s Ozempic. GIP is a metabolic hormone that promotes insulin secretion and also weakly inhibits gastric acid secretion to suppress appetite.

Insulin 98

Insulin Hormones FDA Approval Sales 98

XTalks

NOVEMBER 3, 2022

Demand for Lilly’s GIP/GLP-1 receptor agonist Mounjaro is also rising because of high patient demand since the drug’s May 13 FDA approval and expanding insurance coverage. Mounjaro has thus taken off stronger than expected, surpassing Wall Street sales forecasts during the third quarter.

Sales 98

Sales FDA Approval Production Insulin 98

XTalks

MAY 26, 2022

In this episode, Ayesha discussed the FDA approval of Eli Lilly’s diabetes injection Mounjaro (tirzepatide) for the treatment of adults with type 2 diabetes This is a great advancement in the diabetes space as Mounjaro is a first-in-class medicine that targets the activity of two hormones involved in hunger and blood sugar control (GLP-1 and GIP).

Life Science 52

Life Science FDA Approval Hormones Sales 52

XTalks

JULY 19, 2024

Compounded GLP-1 medications, created by specialized pharmacies under a special US Food and Drug Administration (FDA) allowance due to ongoing shortage, have become increasingly popular for weight loss.

Pharmacy 104

Pharmacy Drugs Production Sales 104

XTalks

FEBRUARY 5, 2024

The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research. Read on to learn more about the top 40 best-selling oncology drugs in 2023, based on 2022 sales data. Price of Revlimid: A supply of 28 oral 2.5 mg capsules is $24,576.

FDA Approval 52

FDA Approval Drugs Sales Development 52

pharmaphorum

AUGUST 8, 2022

Bayer has won a key FDA approval to extend the use of its prostate cancer therapy Nubeqa, as it tries to claim market share from rival drugs and fulfil its aim of building the drug into a €3 billion ($3.1 Last week, Bayer reported sales of Nubeqa doubled in the second quarter of this year to €105 million. billion) blockbuster.

Sales 59

Sales Hormones Marketing FDA Approval 59

XTalks

AUGUST 2, 2023

Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. Paxlovid was first authorized under the FDA Emergency Use Authorization in December 2021 ; however, it has received FDA approval on May 25, 2023. billion in pharmaceutical sales from 2021. billion in 2022, a 23.43

Sales 98

Sales Manufacturing FDA Approval Life Science 98

pharmaphorum

OCTOBER 11, 2020

Pfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set back its hopes of even loftier sales – and set up a challenge from Eli Lilly’s rival drug Verzenio.

Trials 52

Trials HR Hormones Drugs 52

pharmaphorum

MARCH 24, 2022

Novartis has been steadily investing in radiopharmaceuticals over the last few years, and one of those deals has just paid off with an FDA approval for Pluvicto, the first targeted radioligand therapy for prostate cancer.

Hormones 59

Hormones Sales FDA Approval Drugs 59

XTalks

NOVEMBER 20, 2023

AstraZeneca has won its first-in-class approval for its AKT inhibitor Truqap (capivasertib) in combination with Faslodex (fulvestrant) for treating patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. billion to $1.28

HR 98

HR FDA Approval Gene Trials 98

pharmaphorum

JANUARY 26, 2023

In Europe, approximately 531,000 breast cancer patients are diagnosed annually, with around 141,000 deaths, and around half of all cases would fall under the HER2-low classification, split between patients with both hormone receptor (HR) positive and HR negative disease. months to 23.4

HR 52

HR Sales Hormones FDA Approval 52

XTalks

NOVEMBER 9, 2023

Eli Lilly is now fully armed on the GLP-1 front as it’s finally received US Food and Drug Administration (FDA) approval for Zepbound (tirzepatide), its obesity version of Mounjaro. The FDA approved Zepbound for chronic weight management in adults with obesity. Since its approval in May 2022, Mounjaro sales have hit $1.4

FDA Approval 59

FDA Approval Manufacturing Drugs Pharmacy 59

The Pharma Data

MAY 13, 2021

Well, sleep keeps the “hunger hormones” (ghrelin and leptin) in check. When you don’t get enough sleep, you create an imbalance between these hormones and that leads to an increased appetite which, in turn, will put your weight loss journey to a halt. Well, sleep keeps the “hunger hormones” (ghrelin and leptin) in check.

Hormones 52

Hormones Production Packaging Packaging 52

XTalks

MARCH 15, 2023

FDA-approved ADHD-specific non-stimulants are a relatively newer class of medication designed to treat ADHD that have much fewer side effects than stimulants. Norepinephrine is a hormone and neurotransmitter that helps in alertness and maintaining control in high-stress situations. million in net product sales in 2021 to $61.3

Drugs 98

Drugs Sales Trials Marketing 98

XTalks

MARCH 8, 2024

The company also complained that the FDA would make an approval decision on the biosimilar before patent expirations. According to Amgen’s last earnings report , Prolia sales increased 12 percent last year to more than $4 billion, and Xgeva’s jumped five percent from last year to $2.1

Drugs 59

Drugs FDA Approval Production Immune Response 59

Delveinsight

DECEMBER 7, 2020

Unlike most other industries, in MedTech, AI is not confined to sales and operations ends of the value chain. In April 2018, the FDA approved IDx ‘s AI-based diagnostic system for the autonomous detection of diabetic retinopathy, a disorder that can lead to blindness.

Protein 56

Protein Insulin Development Hormones 56

The Pharma Data

AUGUST 3, 2021

Product sales increased 3% globally, driven by double digit volume growth across a number of our products including Prolia ® (denosumab), Repatha ® (evolocumab) and our biosimilar products MVASI ® (bevacizumab-awwb) and KANJINTI ® (trastuzumab-anns). Product Sales Performance. Key results include: Total revenues increased 5% to $6.5

Sales 52

Sales Production Antibody Development 52

The Pharma Data

APRIL 27, 2021

Today’s ODAC meeting is part of an industry-wide review of accelerated approvals with confirmatory trials that have not met their primary endpoint(s) and have yet to gain regular approvals. billion in R&D and posted sales of CHF 58.3 In 2020, Roche invested CHF 12.2 For more information, please visit www.roche.com.

Medicine 40

Medicine In-Vitro Antibody Development 40

The Pharma Data

MAY 4, 2021

Following the completion of the spin-off of the Upjohn Business (4) in the fourth quarter of 2020, Pfizer now operates as a focused innovative biopharmaceutical company engaged in the discovery, development, manufacturing, marketing, sales and distribution of biopharmaceutical products worldwide. Cost of Sales (1). previously $59.4

Vaccination 40

Vaccination Vaccine Production Sales 40

XTalks

AUGUST 10, 2022

In the US, it is estimated that 287,850 new cases of female breast cancer will be diagnosed in 2022, according to data from the National Cancer Institute (NCI) outlined by the FDA. The trial included 494 hormone receptor positive (HR+) patients and 63 hormone receptor negative (HR-) patients.

FDA Approval 98

FDA Approval HR Hormones Antibody 98

STAT News

DECEMBER 5, 2022

Horizon shares surged over the past week after the company said it is in separate preliminary talks with J&J, Amgen, and Sanofi about a possible sale. Meantime, the FDA told ImmunoGen and ADC Therapeutics, which have been developing cancer drugs, that it would not grant a speedy approval until they had begun follow-up studies.

Insulin 52

Insulin Manufacturing Medicine Drugs 52

XTalks

NOVEMBER 26, 2024

The year 2023 was no exception, with several cancer drugs achieving remarkable sales milestones, reflecting their efficacy, expanding indications and the growing global cancer burden. In this blog, we highlight the top 10 cancer drugs to watch in 2024, based on their impressive 2023 sales figures and anticipated market dynamics.

Sales 105

Sales FDA Approval Drugs Marketing 105

XTalks

DECEMBER 6, 2024

While both semaglutide and tirzepatide have a glucagon-like peptide-1 (GLP-1) agonist component, tirzepatide also acts as an agonist of the gastric inhibitory polypeptide (GIP) hormone; this serves as a differentiator between the two and could explain tirzepatides stronger weight loss effects.

Trials 98

Trials Clinical Trials Clinical Trials Marketing 98

Pharmaceutical Technology

MAY 11, 2023

The FDA has no obligations to follow the recommendation of AdComs, though the vote will likely be weighed in the agency’s final decision. The FDA approved Opill for prescription use in 1973. The therapy only contains the hormone progestin and is taken once daily.

FDA Approval 130

FDA Approval Hormones Drugs Containment 130

XTalks

MAY 20, 2022

billion in sales for Lilly by 2026. Mounjaro has a dual-action design as it mimics the action of two hormones involved in blood sugar control, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), making it the first-in-class medicine that activates both of the receptors.

Insulin 52

Insulin Life Science Drugs Sales 52